Dr. Joseph de Beauchamp of World Financial News Network started coverage and gives favorable analysis to Provectus. Provectus develops and markets over-the-counter products for certain skin diseases, including psoriasis and a variety of other skin conditions.
Seattle, WA (PRWEB) March 9, 2005 — Dr. Joseph de Beauchamp of World Financial News Network started coverage and gives favorable analysis to Provectus, which develops and markets over-the-counter products for certain skin diseases, including psoriasis and a variety of other skin conditions.
WFNN consistently outperforms established industry benchmark indicators. Based on in-depth research and analysis, their analysts recommend securities worldwide showing the highest probability for stock price appreciation. With constant vigil, WFNN looks for economic opportunities in the private and public company sectors.
Dr. Joseph de Beauchamp, WFNN's Chief Independent Analyst, said, Provectus shows a robust pipeline of prescription drug candidates and target markets for its OTC products that exceed $1 billion annually. Several significant milestones have been achieved including filing of an Investigational New Drug (IND) application and FDA clearance of the application for the Company's oncology product Provecta(TM) to proceed with Phase 1 human clinical trials.
"Provectus also plans to launch Phase 2 clinical trials for its Psoriasis drug Xantryl(TM). New patent applications have been filed and new patents allowed, increasing the value of the proprietary portfolio. Over-the-counter sales have started and the Company is now selling its Pure-ific(TM) Antibacterial Hand Spray in over 1,000 stores nationwide. WFNN sees the stock moving up to the $3.00 range with these recent developments."
For brief information of this new, dynamic company, examine: http://wfnn.info displaying in the search engine section.
About WFNN:
World Financial News Network provides a unique blend of data, timely information and today's technologies to assist with up-to-the-minute investment and economic values on markets and investments around the world.
About Provectus Pharmaceuticals:
Provectus Pharmaceuticals (OTC Bulletin Board: PVCT) is a pioneering pharmaceutical company actively engaged in the design, development and marketing of a diverse portfolio of leading pharmaceutical technologies for the treatment of melanoma, breast cancer and liver cancer. In addition, Provectus is developing treatments for certain skin diseases, including psoriasis and a variety of other skin conditions. Provectus also has a division that develops and markets over-the-counter products.
Peter Culpepper, CFO
PVCT -- Provectus Pharmaceutical, Inc.
7327 Oak Ridge Highway
Suite A
Knoxville, TN 37931
http://www.pvct.com
856-769-4011
info@pvct.com
# # #
|
